110 results on '"Xu, Christine"'
Search Results
2. The history of CRISPR: from discovery to the present
3. List of contributors
4. AERIFY-1/-2: 2 phase 3 randomised controlled trials of itepekimab in former smokers with moderate-to-severe COPD
5. Multiple Cranial Nerve Palsies in the Setting of Herpes Zoster Ophthalmicus (P1-13.006)
6. Telemedicine retinopathy of prematurity severity score (TeleROP-SS) versus modified activity score (mROP-ActS) retrospective comparison in SUNDROP cohort
7. CRISPR Base Editing in Induced Pluripotent Stem Cells
8. Enhancement of the thermal stability of G-quadruplex structures by urea
9. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma
10. Abstract 2329: Investigating the contribution of distinct regions of the eIF3 complex to mRNA recruitment
11. The Stabilization of G-Quadruplex Structures by Urea
12. Comparative Transcriptional Analyses in the Nucleus Accumbens Identifies RGS2 as a Key Mediator of Depression-Related Behavior
13. REPRODUCTIVE OPHTHALMOLOGY
14. Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults With Moderate-to-Severe Atopic Dermatitis: An Analysis of a Randomized, Double-Blind Phase III Study
15. Combined Model of OCT Angiography and Structural OCT Parameters to Predict Paracentral Visual Field Loss in Primary Open-Angle Glaucoma
16. Insights From the Eye for Patients With Kidney Transplant
17. Pharmacokinetics, pharmacodynamics, and exposure–efficacy of dupilumab in adults with atopic dermatitis
18. Oxytocin receptor behavioral effects and cell types in the bed nucleus of the stria terminalis
19. Targeted Bioavailability
20. Pharmacokinetics, Pharmacodynamics and Safety of Single-Dose Subcutaneous Sarilumab With or Without Methotrexate in Japanese Patients with Rheumatoid Arthritis: Two Single-Dose Studies
21. Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe
22. Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines
23. Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis
24. Insights from the Eye for Patients with Kidney Transplant
25. Endoscopic Cyclophotocoagulation in Boston Keratoprosthesis Type II
26. Understanding Barriers to Treatment among Individuals not Engaged in Treatment who Misuse Opioids: A Structural Equation Modeling Approach
27. Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies
28. Pharmacokinetics and pharmacodynamics of itepekimab in healthy adults and patients with asthma: Phase I first‐in‐human and first‐in‐patient trials
29. Performance of Rapid On-Site Evaluation in Breast Fine-Needle Aspiration Biopsies: Identifying Areas of Diagnostic Challenge
30. Immunogenicity of sarilumab and impact on safety and efficacy in Japanese patients with rheumatoid arthritis: analysis of two Phase 3 randomised clinical trials
31. The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis
32. Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma
33. Unscripted
34. Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children ≥6 to <12 Years of Age Using Phase 3 Data
35. The Effects of Regulator of G-Protein Signaling 2 (RGS2) on Depression-Like Behavior in Female California Mice
36. Out of darkness
37. Awakening
38. The Impact of a Family-Based Economic Intervention on the Mental Health of HIV-Infected Adolescents in Uganda: Results From Suubi + Adherence
39. Ode to a good neighbor
40. Differential Binding of Sarilumab and Tocilizumab to IL‐6Rα and Effects of Receptor Occupancy on Clinical Parameters
41. Compound heterozygous inheritance of two novel COQ2 variants results in familial coenzyme Q deficiency
42. IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies
43. Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects
44. Pharmacokinetics and Pharmacodynamics of Subcutaneous Sarilumab and Intravenous Tocilizumab Following Single‐Dose Administration in Patients With Active Rheumatoid Arthritis on Stable Methotrexate
45. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors
46. Population Pharmacodynamic Model of Neutrophil Margination and Tolerance to Describe Effect of Sarilumab on Absolute Neutrophil Count in Patients with Rheumatoid Arthritis
47. The impact of discomfort with HIV status and hopelessness on depressive symptoms among adolescents living with HIV in Uganda
48. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach
49. Population Pharmacokinetic–Pharmacodynamic Relationships of Sarilumab Using Disease Activity Score 28-Joint C-Reactive Protein and Absolute Neutrophil Counts in Patients with Rheumatoid Arthritis
50. Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.